Comparison of the effect of glycerol and triamcinolone acetonide on cumulative skin irritation in a randomized trial - 12/08/11
Reprint requests: Klaus Ejner Andersen, MD, DMSc, Department of Dermatology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark.Odense and Ballerup, Denmark
Abstract |
Background |
So-called anti-irritants are added to cosmetic formulations because of their alleged beneficial effect on irritated skin. Documentation for these claims is often limited. However, glycerol has shown anti-irritant properties in experimentally induced irritation from sodium lauryl sulfate and nonanoic acid (NON). This study was designed to further substantiate that glycerol added to cosmetic formulations has an anti-irritant effect on experimentally induced skin irritation.
Objective |
We sought to compare glycerol with triamcinolone acetonide as treatments for cutaneous irritation in human volunteers.
Methods |
Irritation was induced by 3 daily arm washes for a week with 10% sodium lauryl sulfate on one arm and 30% NON on the other. To maintain irritation, for the next 12 days volunteers washed their arms twice daily with the irritants. Treatments were applied immediately after washing. The treatments (including vehicle and no treatment) were randomized to sites using a Latin square design. The reactions were evaluated clinically and instrumentally.
Limitations |
Study was designed to only detect potent anti-irritants.
Conclusion |
Glycerol reduced the irritant effect of both sodium lauryl sulfate and NON, whereas triamcinolone acetonide appeared to have beneficial effect only on the irritation induced by NON. The study provided experimental documentation for the claim that glycerol has anti-irritant effect in a cosmetic formulation.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ANCOVA, EOT, ESCD, NON, SLS, TEWL
Plan
| The study was part of a 3-year PhD project financed by University of Southern Denmark and LEO Pharma A/S. Conflicts of interest: None identified. Presented in preliminary form at the proDerm Seminar “Dermatoxicology and Dermatopharmacology,” Hamburg, Germany, on October 10, 2004. |
Vol 56 - N° 2
P. 228-235 - février 2007 Retour au numéro
Article précédent
- Efalizumab for severe atopic dermatitis: A pilot study in adults
- Rodd Takiguchi, Susan Tofte, Brenda Simpson, Erin Harper, Andrew Blauvelt, Jon Hanifin, Eric Simpson
- Registration of clinical trials
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?